JL 18004
Alternative Names: JL-18004Latest Information Update: 10 Jul 2023
At a glance
- Originator JECHO Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 10 Jul 2023 Preclinical trials in Solid tumours in China (unspecified route) before July 2023 (JECHO Biopharmaceuticals pipeline, July 2023)